Denali Therapeutics (DNLI) Research & Development (2017 - 2024)
Historic Research & Development for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to $99.8 million.
- Denali Therapeutics' Research & Development fell 743.58% to $99.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $396.4 million, marking a year-over-year decrease of 647.26%. This contributed to the annual value of $396.4 million for FY2024, which is 647.26% down from last year.
- Denali Therapeutics' Research & Development amounted to $99.8 million in Q4 2024, which was down 743.58% from $98.2 million recorded in Q3 2024.
- Denali Therapeutics' Research & Development's 5-year high stood at $128.8 million during Q1 2023, with a 5-year trough of $51.0 million in Q1 2020.
- Over the past 5 years, Denali Therapeutics' median Research & Development value was $88.8 million (recorded in 2022), while the average stood at $82.9 million.
- Its Research & Development has fluctuated over the past 5 years, first soared by 4961.56% in 2023, then crashed by 1692.34% in 2024.
- Denali Therapeutics' Research & Development (Quarter) stood at $54.7 million in 2020, then rose by 23.99% to $67.9 million in 2021, then skyrocketed by 35.7% to $92.1 million in 2022, then increased by 17.04% to $107.8 million in 2023, then dropped by 7.44% to $99.8 million in 2024.
- Its Research & Development was $99.8 million in Q4 2024, compared to $98.2 million in Q3 2024 and $91.4 million in Q2 2024.